跳至主要内容
临床试验/EUCTR2017-004424-29-NL
EUCTR2017-004424-29-NL进行中(未招募)1 期

Pharmacogenetics Use For Further treatment Improvement in childreN (PUFFIN) trial - PUFFI

Academic Medical Center0 个研究点目标入组 25 人开始时间: 2017年12月21日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • - Between 6-18 years of age
  • - Doctor's diagnosis of asthma (ever) based on patient history, FEV1 reversibility >= 12% ever and/or bronchial
  • hyperresponsiveness ever.
  • - Current asthma symptoms (based on ACT (>= 12 years) or c-ACT (< 12 years) score <= 19
  • ICS use >= 3 months before inclusion (start dosage ICS treatment step 2 according to childhood asthma guideline (NVK))
  • - adequate inhalation technique
  • - self-assessed good adherence to maintenance asthma treatment
  • - understanding of Dutch Language
  • - internet access at home, willing to fill in questionnaires
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 310
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - active smoking
  • - congenital heart disease
  • - serious lung disease other than asthma
  • - LABA use in the past 6 months
  • - omalizumab use
  • - ICU admission in the previous year

研究者

发起方
Academic Medical Center

相似试验